Brokers Offer Predictions for Zimmer Biomet FY2025 Earnings

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Analysts at Zacks Research reduced their FY2025 EPS estimates for shares of Zimmer Biomet in a research note issued to investors on Monday, June 16th. Zacks Research analyst R. Department now expects that the medical equipment provider will earn $7.92 per share for the year, down from their previous forecast of $7.95. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q4 2025 earnings at $2.35 EPS, Q1 2026 earnings at $1.87 EPS, Q2 2026 earnings at $2.09 EPS and Q4 2026 earnings at $2.07 EPS.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The business had revenue of $1.91 billion during the quarter, compared to analysts’ expectations of $1.89 billion. During the same quarter in the prior year, the firm earned $1.94 EPS. The business’s revenue for the quarter was up 1.1% compared to the same quarter last year.

A number of other equities research analysts have also commented on ZBH. Truist Financial set a $101.00 price target on Zimmer Biomet in a research report on Tuesday, May 6th. BTIG Research reiterated a “buy” rating on shares of Zimmer Biomet in a report on Monday, April 14th. Stifel Nicolaus set a $115.00 price target on shares of Zimmer Biomet and gave the stock a “buy” rating in a report on Tuesday, May 6th. JMP Securities dropped their price target on shares of Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Zimmer Biomet from $128.00 to $105.00 and set an “overweight” rating for the company in a research report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus price target of $111.53.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $90.47 on Wednesday. The stock has a market cap of $17.90 billion, a price-to-earnings ratio of 20.02, a P/E/G ratio of 2.09 and a beta of 0.72. The company has a quick ratio of 1.46, a current ratio of 2.44 and a debt-to-equity ratio of 0.53. Zimmer Biomet has a twelve month low of $89.22 and a twelve month high of $116.71. The company’s fifty day moving average is $95.75 and its 200 day moving average is $103.13.

Institutional Investors Weigh In On Zimmer Biomet

A number of institutional investors and hedge funds have recently bought and sold shares of ZBH. Garde Capital Inc. bought a new stake in Zimmer Biomet during the first quarter worth $29,000. Menard Financial Group LLC purchased a new stake in shares of Zimmer Biomet during the 4th quarter valued at $30,000. Washington Trust Advisors Inc. bought a new stake in shares of Zimmer Biomet during the 1st quarter worth $30,000. Columbia River Financial Group LLC purchased a new position in shares of Zimmer Biomet in the 1st quarter worth about $30,000. Finally, Accent Capital Management LLC bought a new position in Zimmer Biomet during the first quarter valued at about $35,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Sang Yi sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the transaction, the insider now owns 20,424 shares in the company, valued at $1,940,280. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.39% of the company’s stock.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.06%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet’s dividend payout ratio (DPR) is 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.